A Review of Natural Therapies Potentially Relevant in Triple Negative Breast Cancer Aimed at Targeting Cancer Cell Vulnerabilities.
HIF
Hedgehog
MAPK
MTAP
NF-Kappa
Notch
P13k
STAT3
TNBC
adaptation
anticancer
biochemical
biomarkers
breast
cancer
compounds
empirical
natural
p53
pathways
pre-clinical
recurrence
suppression
suppression centric anticancer natural strategy (SCANS)
targeted
therapies
translational
treatment
Journal
Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834
Informations de publication
Date de publication:
Historique:
entrez:
27
11
2020
pubmed:
28
11
2020
medline:
19
8
2021
Statut:
ppublish
Résumé
We reviewed the research into the mechanisms of growth of triple negative breast cancer (TNBC) based on laboratory pre-clinical studies that have shaped understanding of the disease over the past decade. In response to these findings, we propose an approach to potentially prevent cancer metabolic adaptation and recurrence. This paper collates pre-clinical results, first to determine the tumor's mechanisms of growth and then to source natural substances that could potentially suppress those mechanisms. The results from in vivo and in vitro studies of TNBC were combined first to select 10 primary mechanisms (Hypoxia-inducible factor 1α, Hedgehog, MAPK, MTAP, NF-κ B, Notch, P13K, STAT3, and Wnt signaling pathways plus
Identifiants
pubmed: 33243021
doi: 10.1177/1534735420975861
pmc: PMC7705812
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1534735420975861Références
Oncotarget. 2017 Jan 31;8(5):8226-8238
pubmed: 28030809
Life Sci. 2018 Nov 15;213:149-157
pubmed: 30352240
J Cell Physiol. 2015 Apr;230(4):853-62
pubmed: 25204544
Pharmacol Res. 2019 Apr;142:1-13
pubmed: 30735802
Cancers (Basel). 2019 Apr 18;11(4):
pubmed: 31003514
J Agric Food Chem. 2016 Jul 13;64(27):5515-24
pubmed: 27327035
Cancer Lett. 2015 Mar 1;358(1):1-7
pubmed: 25528630
Sci Rep. 2013;3:2256
pubmed: 23884293
Br J Cancer. 2017 May 23;116(11):1425-1435
pubmed: 28441382
J Biol Chem. 1995 Oct 20;270(42):24995-5000
pubmed: 7559628
Annu Rev Pathol. 2009;4:127-50
pubmed: 18767981
BMC Complement Altern Med. 2013 Aug 03;13:203
pubmed: 23914993
Emerg Med Int. 2020 Feb 1;2020:1264714
pubmed: 32076577
Breast Cancer Res Treat. 2016 May;157(1):41-54
pubmed: 27097807
PLoS One. 2009 Sep 03;4(9):e6896
pubmed: 19727403
J Biol Chem. 2014 Nov 7;289(45):30962-76
pubmed: 25231991
J Biol Chem. 2013 Oct 25;288(43):31280-8
pubmed: 24019511
Planta Med. 1998 May;64(4):353-6
pubmed: 9619120
Thorax. 2017 Sep;72(9):780-787
pubmed: 28250200
Biomed Pharmacother. 2017 Oct;94:898-908
pubmed: 28810530
J Oncol. 2019 Jul 11;2019:8707053
pubmed: 31379945
Mol Cancer Ther. 2006 Mar;5(3):621-9
pubmed: 16546976
Mitochondrion. 2010 Nov;10(6):614-25
pubmed: 20713185
Am J Epidemiol. 2006 Apr 1;163(7):645-53
pubmed: 16484447
Nat Rev Mol Cell Biol. 2016 Jul;17(7):451-9
pubmed: 26979502
FEBS J. 2008 Aug;275(16):4111-20
pubmed: 18625006
Oncol Rep. 2017 Feb;37(2):895-902
pubmed: 27959422
Cell Death Dis. 2018 Dec 5;9(12):1167
pubmed: 30518934
Cancer Res. 2010 Mar 15;70(6):2445-54
pubmed: 20215512
Oncol Lett. 2012 Jan;3(1):163-171
pubmed: 22740874
Oncogene. 2012 Jan 5;31(1):104-15
pubmed: 21666711
Int J Oncol. 2018 Oct;53(4):1469-1480
pubmed: 30066852
Oncotarget. 2016 Feb 23;7(8):9250-70
pubmed: 26843616
PLoS One. 2012;7(7):e41586
pubmed: 22911819
Biochim Biophys Acta. 2014 Apr;1845(2):136-54
pubmed: 24388873
Nat Metab. 2020 Apr;2(4):335-350
pubmed: 32694609
PLoS One. 2014 Sep 03;9(9):e106966
pubmed: 25184276
Int J Oncol. 2017 Feb;50(2):727-735
pubmed: 28035371
Cell Chem Biol. 2017 Sep 21;24(9):1161-1180
pubmed: 28938091
Cancer Res. 2010 Oct 1;70(19):7392-9
pubmed: 20841478
Cancer. 2007 May 1;109(9):1721-8
pubmed: 17387718
Oncol Rep. 2017 Jul;38(1):598-606
pubmed: 28560452
Toxicol Res (Camb). 2016 Jan 21;5(3):800-807
pubmed: 30090390
Int J Clin Exp Pathol. 2014 May 15;7(6):2818-24
pubmed: 25031701
Int J Occup Med Environ Health. 2002;15(3):209-18
pubmed: 12462448
Oncogene. 2012 Apr 5;31(14):1757-70
pubmed: 21860410
Front Pharmacol. 2019 Oct 14;10:1171
pubmed: 31680955
Oncologist. 2018 Jun;23(6):658-e72
pubmed: 29511132
PLoS One. 2015 Feb 06;10(2):e0117440
pubmed: 25659153
Pharmaceuticals (Basel). 2019 Oct 26;12(4):
pubmed: 31717764
Food Chem Toxicol. 2017 Sep;107(Pt A):502-519
pubmed: 28755953
PLoS One. 2009 May 29;4(5):e5735
pubmed: 19478948
Mar Drugs. 2018 Nov 10;16(11):
pubmed: 30423844
Int J Surg Oncol. 2015;2015:785793
pubmed: 25685551
Oncogene. 1999 Dec 13;18(53):7666-75
pubmed: 10618706
Cancer Genet Cytogenet. 2010 Jul 1;200(1):23-7
pubmed: 20513530
Yonsei Med J. 2017 May;58(3):489-496
pubmed: 28332352
Cell Res. 2014 Aug;24(8):904-5
pubmed: 24810303
Biochim Biophys Acta. 2016 Mar;1863(3):382-391
pubmed: 26079100
Exp Mol Pathol. 2015 Jun;98(3):313-27
pubmed: 25818165
Oncogene. 1999 May 20;18(20):3166-72
pubmed: 10340389
Nat Nanotechnol. 2019 Apr;14(4):388-397
pubmed: 30804480
Front Pharmacol. 2019 Sep 19;10:1071
pubmed: 31607920
Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304
pubmed: 26590477
PLoS One. 2012;7(4):e33656
pubmed: 22485147
Biochemistry (Mosc). 2015 Aug;80(8):972-89
pubmed: 26547065
PLoS One. 2017 Dec 27;12(12):e0189864
pubmed: 29281678
J Vasc Res. 2014;51(4):315-24
pubmed: 25322777
Drug Deliv. 2020 Dec;27(1):137-150
pubmed: 31913733
Cancer Prev Res (Phila). 2017 Jun;10(6):363-370
pubmed: 28400479
BMC Cancer. 2020 Jan 2;20(1):4
pubmed: 31898540
OMICS. 2017 Apr;21(4):225-231
pubmed: 28388298
Nat Rev Cancer. 2004 Jun;4(6):437-47
pubmed: 15170446
Oncogene. 2018 May;37(19):2502-2514
pubmed: 29449694
Clin Cancer Res. 2013 Jul 15;19(14):3738-44
pubmed: 23748695
Cancer Prev Res (Phila). 2019 Mar;12(3):147-158
pubmed: 30679159
Cytokine. 2017 Oct;98:42-50
pubmed: 28579221
Breast Cancer (Dove Med Press). 2016 Dec 23;9:9-19
pubmed: 28096694
J Clin Med. 2019 Jan 27;8(2):
pubmed: 30691241
Cancer Res. 2004 Oct 15;64(20):7513-25
pubmed: 15492278
Science. 1999 Apr 30;284(5415):770-6
pubmed: 10221902
DNA Cell Biol. 2018 Aug;37(8):697-707
pubmed: 29969282
Cancer Treat Rev. 2012 Oct;38(6):726-36
pubmed: 22342103
Oncotarget. 2016 Oct 11;7(41):67223-67234
pubmed: 27579534
Cell Cycle. 2003 Jul-Aug;2(4):339-45
pubmed: 12851486
Cancer Res. 2007 May 1;67(9):4157-63
pubmed: 17483326
Minerva Med. 2017 Aug;108(4):334-340
pubmed: 28248066
PLoS One. 2015 Apr 30;10(4):e0123781
pubmed: 25927362
Toxicology. 2019 Apr 15;418:22-31
pubmed: 30797898
Cancer Prev Res (Phila). 2013 Oct;6(10):1120-7
pubmed: 23985577
J Nutr. 2006 Mar;136(3 Suppl):816S-820S
pubmed: 16484572
PLoS One. 2016 Jan 11;11(1):e0145647
pubmed: 26751376
J Cancer Prev. 2014 Mar;19(1):23-30
pubmed: 25337569
Science. 1991 Jul 5;253(5015):49-53
pubmed: 1905840
Cell Physiol Biochem. 2018;50(5):1945-1963
pubmed: 30396169
Dev Cell. 2008 Dec;15(6):801-12
pubmed: 19081070
Oncotarget. 2013 Feb;4(2):329-45
pubmed: 23593654
Cancer Res. 2016 Jun 1;76(11):3397-410
pubmed: 27197172
Phytomedicine. 2019 Feb;53:213-222
pubmed: 30668401
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2015 Mar 10;6(7):4585-601
pubmed: 25671304
Front Oncol. 2018 Dec 04;8:575
pubmed: 30564555
Oncol Lett. 2019 Jul;18(1):330-338
pubmed: 31289504
Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2312-22
pubmed: 23917455
Int J Mol Med. 2009 Apr;23(4):469-75
pubmed: 19288022
Oncotarget. 2017 Jan 3;8(1):329-344
pubmed: 27861147
Biomed Pharmacother. 2017 May;89:227-232
pubmed: 28231544
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2707-16
pubmed: 23012449
Onco Targets Ther. 2020 Jan 13;13:323-335
pubmed: 32021278
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Front Cell Infect Microbiol. 2019 Jul 23;9:267
pubmed: 31396491